Cognitive factors influencing treatment decision-making in patients with localised prostate cancer: development of a standardised questionnaire. Issue 4 (August 2015)

• Record Type: Journal Article
• Authors: Devos, J.; Van Praet, C.; Decaestecker, K.; Claeys, T.; Fonteyne, V.; Decalf, V.; De Meerleer, G.; Ost, P.; Lumen, N.
• Is Part Of: Acta clinica belgica. Volume 70:Issue 4(2015)
• Page Start: 272
• Page End: 279
• Publication Date: 2015-08
• Subjects: Prostatic neoplasms, -- Localised prostate cancer, -- Informed decision making, -- Treatment decision making, -- Treatment choice; Clinical medicine -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.005
• DOI: 10.1179/2295333715Y.0000000015
• Languages: English
• ISSNs: 1784-3286

Abstract

Abstract : Background: Men diagnosed with localised prostate cancer have to make a well-informed treatment choice between (robot-assisted) radical prostatectomy, external beam radiotherapy and, in selected cases, brachytherapy and active surveillance. We developed and validated a questionnaire to determine the cognitive reasons motivating this choice. Materials and methods: The Prostate Cancer Decision-Making Questionnaire (PC-DMQ) was designed in-house and validated through the Delphi method. Finally, we tested the questionnaire in a cohort of 24 men, recently diagnosed with localised PC, before undergoing RARP (n = 16), EBRT (n = 6), brachytherapy (n = 1) or active surveillance (n = 1). Results: The experts reached consensus after three rounds. In the patient cohort, 75% of men undergoing RARP chose this treatment because 'it provides the best chance of cure'. Reasons to choose EBRT were not as explicit: 33.3% chose this treatment because 'it provides the best chance of cure' and 33.3% because 'the maintenance of potency is important to them'. Conclusions: The PC-DMQ is a comprehensive and standardised tool that allows further research into cognitive factors that influence treatment decision-making in patients with localised PC.